keyword
MENU ▼
Read by QxMD icon Read
search

mucolytic

keyword
https://www.readbyqxmd.com/read/29683370/nutritional-supplement-bao-khi-khang-as-an-adjuvant-therapy-in-acute-exacerbations-of-chronic-obstructive-pulmonary-disease
#1
Ba X Hoang, Bo Han, Hoang X Nguyen, Khanh T Dang
To investigate the effectiveness of nutritional supplement Bao Khi Khang as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to conventional therapy alone. This was a prospective, randomized, open-label controlled trial in 60 patients presenting with acute exacerbation of COPD. Patients were randomized into two groups, the control and the experimental groups. The control group was treated with the standard therapeutic protocol (Antimicrobial+Corticosteroids+Bronchodilator+Mucolytic drugs)...
April 23, 2018: Journal of Medicinal Food
https://www.readbyqxmd.com/read/29669663/nonprescription-medications-for-respiratory-symptoms-facts-and-marketing-fictions
#2
Miles Weinberger, Leslie Hendeles
BACKGROUND: There are many nonprescription (over-the-counter [OTC]) medications available on pharmacy shelves marketed for relief of respiratory symptoms. The number of such medications has been increasing. OBJECTIVE: This review provides an evidence-based examination of OTC products used for respiratory symptoms. METHODS: Antihistamines, decongestants, mucolytics, antitussives, and intranasal steroids were selected as the most common OTC medications taken by adults and children for various respiratory symptoms...
May 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29566906/action-and-function-of-akkermansia-muciniphila-in-microbiome-ecology-health-and-disease
#3
REVIEW
Noora Ottman, Sharon Y Geerlings, Steven Aalvink, Willem M de Vos, Clara Belzer
The discovery of Akkermansia muciniphila has opened new avenues for the use of this abundant intestinal symbiont in next generation therapeutic products, as well as targeting microbiota dynamics. A. muciniphila is known to colonize the mucosal layer of the human intestine where it triggers both host metabolic and immune responses. A. muciniphila is particularly effective in increasing mucus thickness and increasing gut barrier function. As a result host metabolic markers ameliorate. The mechanism of host regulation is thought to involve the outer membrane composition, including the type IV pili of A...
December 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/29540496/exacerbations-of-copd
#4
Christian Viniol, Claus F Vogelmeier
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed...
March 31, 2018: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29527305/influenza-and-influenza-like-syndromes-the-subjects-beliefs-the-attitude-to-prevention-and-treatment-and-the-impact-in-italian-general-population
#5
Roberto W Dal Negro, Alessandro Zanasi, Paola Turco, Massimiliano Povero
Background: Influenza and influenza-like syndromes (I-LSs) are infectious diseases occurring on a seasonal basis which can lead to upper (URTI) and lower respiratory tract illness (LRTI) of different severity. The approach to these disorders is unfortunately not uniform. Aim of the study was to investigate real-life people beliefs, the attitude to their prevention and treatment, and their impact in general population. Methods: A cross-sectional survey via Computer Assisted Telephone Interview (CATI) was carried out using a specific questionnaire investigating influenza episode rates, subjects behavior in case of influenza and I-LSs, and prescribed therapy...
2018: Multidisciplinary Respiratory Medicine
https://www.readbyqxmd.com/read/29521616/n-acetyl-cysteine-increases-the-replication-of-chlamydia-pneumoniae-and-prolongs-the-clearance-of-the-pathogen-from-mice
#6
Dávid Kókai, Tímea Mosolygó, Dezső P Virók, Valéria Endrész, Katalin Burián
PURPOSE: Within the community, 10 % of acquired pneumonia is caused by Chlamydia pneumoniae. N-acetyl-cysteine (NAC) is one of the most commonly used mucolytics in respiratory diseases, but its effect on C. pneumoniae infection has not yet been investigated. In this study, our aim was to investigate whether NAC influences the replication of C. pneumoniae. After determining that NAC does have an effect on C. pneumoniae replication, the effect of an alternative drug called Ambroxol (Ax) was investigated...
March 9, 2018: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/29486489/effect-of-on-demand-vs-routine-nebulization-of-acetylcysteine-with-salbutamol-on-ventilator-free-days-in-intensive-care-unit-patients-receiving-invasive-ventilation-a-randomized-clinical-trial
#7
David M P van Meenen, Sophia M van der Hoeven, Jan M Binnekade, Corianne A J M de Borgie, Maruschka P Merkus, Frank H Bosch, Henrik Endeman, Jasper J Haringman, Nardo J M van der Meer, Hazra S Moeniralam, Mathilde Slabbekoorn, Marcella C A Muller, Willemke Stilma, Bart van Silfhout, Ary Serpa Neto, Hans F M Ter Haar, Jan Van Vliet, Jan Willem Wijnhoven, Janneke Horn, Nicole P Juffermans, Paolo Pelosi, Marcelo Gama de Abreu, Marcus J Schultz, Frederique Paulus
Importance: It remains uncertain whether nebulization of mucolytics with bronchodilators should be applied for clinical indication or preventively in intensive care unit (ICU) patients receiving invasive ventilation. Objective: To determine if a strategy that uses nebulization for clinical indication (on-demand) is noninferior to one that uses preventive (routine) nebulization. Design, Setting, and Participants: Randomized clinical trial enrolling adult patients expected to need invasive ventilation for more than 24 hours at 7 ICUs in the Netherlands...
February 27, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29460206/deciphering-the-trophic-interaction-between-akkermansia-muciniphila-and-the-butyrogenic-gut-commensal-anaerostipes-caccae-using-a-metatranscriptomic-approach
#8
Loo Wee Chia, Bastian V H Hornung, Steven Aalvink, Peter J Schaap, Willem M de Vos, Jan Knol, Clara Belzer
Host glycans are paramount in regulating the symbiotic relationship between humans and their gut bacteria. The constant flux of host-secreted mucin at the mucosal layer creates a steady niche for bacterial colonization. Mucin degradation by keystone species subsequently shapes the microbial community. This study investigated the transcriptional response during mucin-driven trophic interaction between the specialised mucin-degrader Akkermansia muciniphila and a butyrogenic gut commensal Anaerostipes caccae. A...
February 19, 2018: Antonie Van Leeuwenhoek
https://www.readbyqxmd.com/read/29455115/therapeutic-use-of-heparin-and-derivatives-beyond-anticoagulation-in-patients-with-bronchial-asthma-or-copd
#9
REVIEW
Janis K Shute, Ermanno Puxeddu, Luigino Calzetta
In this review, we identify potential targets for the therapeutic effects of heparin in asthma and chronic obstructive pulmonary disease (COPD), consider the safety and delivery modalities of this therapeutic approach. Specifically, we point to the anti-inflammatory, antioxidant and mucolytic effects of unfractionated heparin with potential to modify disease progression in COPD and asthma when administered via the inhaled route. Inhaled heparin may represent an effective add-on therapy in COPD and asthma patient groups, especially when taking into consideration the relative deficiency in endogenous heparin reported in asthma patients...
February 15, 2018: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29441886/effects-and-mechanisms-of-ambroxol-inhalation-mucosolvan-%C3%A2-in-the-treatment-of-neonatal-pneumonia
#10
Zuqin Yang, Xiuman Xiao, Yumei Huang, Xiaoxiao He, Qinqin Lu, Shangqin Chen, Zhenlang Lin
Neonatal pneumonia is the leading cause of mortality in children aged <5 years. Ambroxol (Mucosolvan®) is a mucolytic and secretolytic drug and belongs to the group of expectorants with anti-oxidative and anti-inflammatory effects. The purpose of the present study was to observe the effects and mechanisms of Mucosolvan ® inhalation on neonatal pneumonia. Between January 2014 and October 2015, a total of 80 newborns with pneumonia were randomly divided into control and observation groups. While the patients in the control group were treated with conventional treatment only, those patients in the observation group were treated with Mucosolvan® in addition to the conventional treatment...
October 1, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29425465/excess-mucin-impairs-subglottic-epithelial-host-defense-in-mechanically-ventilated-patients
#11
Jason Powell, James Garnett, Michael W Mather, Faye A H Cooles, Andrew Nelson, Bernard Verdon, Jon Scott, Kasim Jiwa, Marie-Hélène Ruchaud-Sparagano, Stephen P Cummings, John D Perry, Stephen E Wright, Janet A Wilson, Jeffrey Pearson, Chris Ward, A John Simpson
RATIONALE: Aspiration of infective subglottic secretions causes ventilator-associated pneumonia (VAP) in mechanically ventilated patients. Mechanisms underlying subglottic colonization in critical illness have not been defined, limiting strategies for targeted prevention of VAP. OBJECTIVES: To characterize subglottic host defense dysfunction in mechanically ventilated patients in the intensive care unit (ICU). To determine whether subglottic mucin contributes to neutrophil phagocytic impairment and bacterial growth...
February 9, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29424930/inhaled-mannitol-for-cystic-fibrosis
#12
REVIEW
Sarah J Nevitt, Judith Thornton, Clare S Murray, Tiffany Dwyer
BACKGROUND: Several agents are used to clear secretions from the airways of people with cystic fibrosis. Mannitol increases mucociliary clearance, but its exact mechanism of action is unknown. The dry powder formulation of mannitol may be more convenient and easier to use compared with established agents which require delivery via a nebuliser. Phase III trials of inhaled dry powder mannitol for the treatment of cystic fibrosis have been completed and it is now available in Australia and some countries in Europe...
February 9, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29391364/overuse-of-diagnostic-tools-and-medications-in-acute-rhinosinusitis-in-spain-a-population-based-study-the-prosinus-study
#13
Francesca Jaume, Llorenç Quintó, Isam Alobid, Joaquim Mullol
OBJECTIVES: Acute rhinosinusitis (ARS) has a high incidence. Diagnosis is clinical, and evolution is mostly self-limited. The aim of this study was to describe the sociodemographic characteristics and use of diagnostic tools and medications in patients with ARS. DESIGN: This is a prospective observational study in real-life clinical practice. SETTING: Patients with clinical diagnosis of ARS (n=2610) were included from ear, nose and throat clinics in Spain...
January 31, 2018: BMJ Open
https://www.readbyqxmd.com/read/29338445/investigational-inhaled-therapies-for-non-cf-bronchiectasis
#14
REVIEW
Sabina Antonela Antoniu
Bronchiectasis not related to cystic fibrosis (non-CF bronchiectasis) are associated with a high unmet therapeutic need due to the lack of specifically authorized medications, especially via the inhalation route. In non-CF bronchiectasis chronic infection with Pseudomonas aeruginosa is common and favored by the persistent local inflammation and viscid sputum production. Therefore inhaled antibiotics, mucolytics or anti-inflammatory agents could represent appropriate therapeutic interventions in this setting Areas covered: This review herein discusses the inhaled therapies currently under investigation for non-CF bronchiectasis and their potential therapeutic positioning in exacerbation versus stable state...
February 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29332002/the-implementation-of-a-cystic-fibrosis-annual-review-process-in-a-tertiary-paediatric-hospital
#15
Raffaela Armiento, Sarath C Ranganathan, Joanne Harrison
We evaluated the implementation of a cystic fibrosis annual review process in a tertiary paediatric hospital. After implementation, there was demonstrated improvement in an important outcome measure-the use of inhaled mucolytic agents.
January 13, 2018: Archives of Disease in Childhood. Education and Practice Edition
https://www.readbyqxmd.com/read/29316973/kartagener-s-syndrome-a-case-report
#16
Abilo Tadesse, Hailemariam Alemu, Mezgebu Silamsaw, Yonathan Gebrewold
BACKGROUND: Kartagener's syndrome is a subset of primary ciliary dyskinesia, an autosomal recessive inherited disorder characterized by the clinical triad of chronic sinusitis, bronchiectasis, and situs inversus. Abnormal ciliary structure or function leading to impaired ciliary motility is the main pathophysiologic problem in Kartagener's syndrome. CASE PRESENTATION: A 24-year-old man from Gondar town, North-West Ethiopia, presented to University of Gondar Hospital with recurrent episodes of nasal congestion with itching and paranasal discomfort, and productive cough for more than a decade...
January 10, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29313589/role-of-clarithromycin-in-acute-exacerbations-of-chronic-obstructive-pulmonary-disease
#17
Agam Vora
The prevalence of chronic obstructive pulmonary disease (COPD) is increasing in under-developing and developing countries. As per current estimations, COPD will become the third leading cause of death globally, by 2030. Long-acting anti-cholinergic agents, β2-agonists, inhaled corticosteroids, antibiotics and mucolytics are few of the agents currently used in the treatment of COPD, which improve the symptoms and overall quality of life. Several of the important classes of antibiotics are used in the management of COPD including penicillins, cephalosporins, tetracyclines, fluoroquinolones, sulphonamides, aminoglycosides and macrolides...
September 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/29303286/-cystic-fibrosis-in-adults
#18
Libor Fila
Cystic fibrosis (CF) is an inherited disease caused by mutations in the transmembrane conductance regulator (CFTR) gene. The disease leads to dysfunction of the exocrine glands with high concentration of chloride in the sweat and formation of abnormally viscous mucus in the respiratory, digestive and reproductive tract. Chronic sinopulmonary disease, exocrine pancreatic insufficiency, liver disease, intestinal obstruction, impaired nutritional status, salt loss syndrome and male infertility dominates in the clinical presentation...
December 0: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29283098/electrophysiological-and-histopathological-evaluation-of-effects-of-sodium-2-mercaptoethanesulfonate-used-for-middle-ear-surgery-on-facial-nerve-functions
#19
Oğuz Kadir Eğilmez, Numan Kökten, Mustafa Baran, M Tayyar Kalcıoğlu, Işın Doğan Ekici, Muhammet Tekin
OBJECTIVE: Sodium-2-mercaptoethanesulfonate (MESNA) is widely used in medicine because of its antioxidant and mucolytic effects. In recent years, it has been used in otologic surgery. Because it cleaves disulfide bonds, it is used to easily dissect the epithelial matrix in cholesteatoma and atelectasis. In this study, we hypothesized that MESNA does not have any toxic effect on the facial nerve, and the effects of MESNA on the facial nerve were examined histologically and electrophysiologically...
December 14, 2017: Journal of International Advanced Otology
https://www.readbyqxmd.com/read/29247764/efficacy-and-safety-concerns-over-the-use-of-mucus-modulating-agents-for-drug-delivery-using-nanoscale-systems
#20
REVIEW
Peter I Chater, Matthew D Wilcox, Jeffrey P Pearson
Drug delivery to the mucus covered mucosae is fraught with difficulties and many different approaches have been developed to permeate the mucus barrier. Generally by modifying the delivery system to avoid interaction with the mucus. These modifications are reviewed here in terms of efficacy and safety. These are particular problems for oral delivery the pharmaceutical industry's favoured route for drug administration. For effective delivery through the gastrointestinal tract a drug must pass through three barriers in sufficient amounts to yield a biological effect...
January 15, 2018: Advanced Drug Delivery Reviews
keyword
keyword
102954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"